Regarding the secondary endpoints, the CRR in subjects receiving 7.5 mg/day, and the reduction of UPCR <0.8 without an intercurrent event were significantly higher in the obinutuzumab arm compared with placebo, while the eGFR endpoint did not reach statistical significance (Fig. 1 ).
1
—
—